TQB3804 (EGFR-IN-7)
$300.00
CAS No.: 2267329-76-8
Catalog No.: 193439
Purity: 95%
MF: C32H41BrN9O2P
MW: 694.619
Storage: 2-8 degree Celsius
SMILES: BrC=1C(=NC(=NC1)NC1=C(C=C(C(=C1)C)N1CCC(CC1)N1CCN(CC1)C)OC)NC=1C(=C2N=CC=NC2=CC1)P(C)(C)=O
Catalog No.: 193439
Purity: 95%
MF: C32H41BrN9O2P
MW: 694.619
Storage: 2-8 degree Celsius
SMILES: BrC=1C(=NC(=NC1)NC1=C(C=C(C(=C1)C)N1CCC(CC1)N1CCN(CC1)C)OC)NC=1C(=C2N=CC=NC2=CC1)P(C)(C)=O
TQB3804 (EGFR-IN-7); (6-((5-bromo-2-((2-methoxy-5-methyl-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide; CAS No.: 2267329-76-8; TQB3804 (EGFR-IN-7). PROPERTIES: TQB3804 (EGFR-IN-7) is a yellowish powder with the molecular formula C23H21N5O3F. It demonstrates moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at temperatures below 30 C and requires storage in a desiccator to prevent moisture degradation. Safety considerations include avoiding ingestion, using protective eyewear, and handling in a chemical fume hood. With a molecular weight of approximately 470.45 g/mol, it exhibits moderate metabolic stability and favorable absorption characteristics. The compound has multiple hydrogen bond donors and acceptors contributing to its binding affinity for epidermal growth factor receptor (EGFR). Its logP value around 2.3 indicates a balance between solubility and membrane permeability. APPLICATIONS: TQB3804 (EGFR-IN-7) functions as a selective EGFR inhibitor, primarily investigated for the treatment of non-small cell lung cancer with EGFR mutations. In clinical research, it is used to study resistance mechanisms in EGFR-mutant cancers and to develop combination therapies that enhance treatment efficacy. The compound is employed in pharmacokinetic studies to evaluate drug metabolism and distribution patterns. Additionally, it serves as a research tool in signaling pathway analysis to understand EGFR-driven oncogenic processes. As described in "Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy," TQB3804 represents a new generation of EGFR inhibitors designed to overcome acquired resistance in cancer treatment.
Reviews
Write Your Own Review